Korro Bio, Inc.
KRRO
$10.59
-$0.35-3.20%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
4/6/2026
-
MarketBeat
Korro Bio (KRRO, $10.72) entered Downtrend as Momentum indicator drops below 0 level on Jun 05, 2026
6/7/2026
-
Tickeron - Stocks
6/7/2026
-
Tickeron - Stocks
6/7/2026
-
Tickeron - Stocks
6/2/2026
-
MarketBeat
5/30/2026
-
The Cerbat Gem
5/29/2026
-
Tickeron - Stocks
5/27/2026
-
Globe Newswire
5/27/2026
-
Tickeron - Stocks
5/27/2026
-
Tickeron - Stocks
5/26/2026
-
TipRanks Financial Blog
5/24/2026
-
Tickeron - Stocks
5/23/2026
-
Tickeron - Stocks
5/22/2026
-
Tickeron - Stocks
5/21/2026
-
MarketBeat
5/21/2026
-
Tickeron - Stocks
5/21/2026
-
Tickeron - Stocks
5/20/2026
-
Tickeron - Stocks
5/19/2026
-
Globe Newswire
5/19/2026
-
Tickeron - Stocks
5/18/2026
-
TipRanks Financial Blog
5/16/2026
-
Tickeron - Stocks
5/15/2026
-
Globe Newswire
5/15/2026
-
Tickeron - Stocks
5/14/2026
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, May 7, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 468 1999
Address
60 First Street
2nd Floor - Suite 250
Cambridge, MA 02141
2nd Floor - Suite 250
Cambridge, MA 02141
Country
Year Founded
Business Description
Sector
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent...
more